121 related articles for article (PubMed ID: 20181461)
1. Time course of antipsychotic treatment response in schizophrenia: results from a naturalistic study in 280 patients.
Jäger M; Riedel M; Obermeier M; Schennach-Wolff R; Seemüller F; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Kühn KU; Lemke MR; Rüther E; Klingberg S; Gastpar M; Bottlender R; Möller HJ
Schizophr Res; 2010 May; 118(1-3):183-8. PubMed ID: 20181461
[TBL] [Abstract][Full Text] [Related]
2. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS
Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566
[TBL] [Abstract][Full Text] [Related]
3. Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder.
Schennach-Wolff R; Meyer S; Seemüller F; Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Möller HJ; Riedel M
J Psychiatr Res; 2011 Dec; 45(12):1639-47. PubMed ID: 21862035
[TBL] [Abstract][Full Text] [Related]
4. One-year functional outcomes of naturalistically treated patients with schizophrenia.
Spellmann I; Riedel M; Schennach R; Seemüller F; Obermeier M; Musil R; Jäger M; Schmauß M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Möller HJ
Psychiatry Res; 2012 Aug; 198(3):378-85. PubMed ID: 22421065
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
Bobes J; Arango C; Garcia-Garcia M; Rejas J;
J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
[TBL] [Abstract][Full Text] [Related]
6. Early improvement as a predictor of remission and response in schizophrenia: Results from a naturalistic study.
Jäger M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Degner D; Buchkremer G; Gastpar M; Möller HJ; Riedel M
Eur Psychiatry; 2009 Dec; 24(8):501-6. PubMed ID: 19559572
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of two alternative schizophrenia remission definitions: relationship to clinical and quality of life outcomes.
Dunayevich E; Sethuraman G; Enerson M; Taylor CC; Lin D
Schizophr Res; 2006 Sep; 86(1-3):300-8. PubMed ID: 16860974
[TBL] [Abstract][Full Text] [Related]
8. Outcome of suicidal patients with schizophrenia: results from a naturalistic study.
Schennach-Wolff R; Jäger M; Seemüller F; Obermeier M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Möller HJ; Riedel M
Acta Psychiatr Scand; 2010 May; 121(5):359-70. PubMed ID: 19878135
[TBL] [Abstract][Full Text] [Related]
9. Prediction of symptom remission in schizophrenia during inpatient treatment.
Jäger M; Riedel M; Schmauss M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Kühn KU; Lemke MR; Rüther E; Buchkremer G; Gastpar M; Bottlender R; Strauss A; Möller HJ
World J Biol Psychiatry; 2009; 10(4 Pt 2):426-34. PubMed ID: 17853260
[TBL] [Abstract][Full Text] [Related]
10. Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders.
Schennach-Wolff R; Jäger M; Seemüller F; Obermeier M; Messer T; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Huff W; Heuser I; Maier W; Lemke MR; Rüther E; Buchkremer G; Gastpar M; Möller HJ; Riedel M
Schizophr Res; 2009 Sep; 113(2-3):210-7. PubMed ID: 19560901
[TBL] [Abstract][Full Text] [Related]
11. Testosterone in first-episode schizophrenia.
Cesková E; Prikryl R; Kaspárek T
Neuro Endocrinol Lett; 2007 Dec; 28(6):811-4. PubMed ID: 18063925
[TBL] [Abstract][Full Text] [Related]
12. Clinical Global Impression of Improvement (CGI-I) as a valid proxy measure for remission in schizophrenia: analyses of ziprasidone clinical study data.
Masand P; O'Gorman C; Mandel FS
Schizophr Res; 2011 Mar; 126(1-3):174-83. PubMed ID: 21185155
[TBL] [Abstract][Full Text] [Related]
13. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
[TBL] [Abstract][Full Text] [Related]
14. Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2012 Jun; 73(6):856-64. PubMed ID: 22687813
[TBL] [Abstract][Full Text] [Related]
15. Depressive symptoms and their association with acute treatment outcome in first-episode schizophrenia patients: comparing treatment with risperidone and haloperidol.
Riedel M; Mayr A; Seemüller F; Maier W; Klingberg S; Heuser I; Klosterkötter J; Gastpar M; Schmitt A; Sauer H; Schneider F; Gaebel W; Jäger M; Möller HJ; Schennach-Wolff R
World J Biol Psychiatry; 2012 Jan; 13(1):30-8. PubMed ID: 21568628
[TBL] [Abstract][Full Text] [Related]
16. Equipercentile linking of the BPRS and the PANSS.
Leucht S; Rothe P; Davis JM; Engel RR
Eur Neuropsychopharmacol; 2013 Aug; 23(8):956-9. PubMed ID: 23433639
[TBL] [Abstract][Full Text] [Related]
17. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study.
Levine SZ; Rabinowitz J; Ascher-Svanum H; Faries DE; Lawson AH
Schizophr Res; 2011 Dec; 133(1-3):42-6. PubMed ID: 22000938
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
[TBL] [Abstract][Full Text] [Related]
19. Patient-based and clinician-based support for the remission criteria in schizophrenia.
Docherty JP; Bossie CA; Lachaux B; Bouhours P; Zhu Y; Lasser R; Gharabawi GM
Int Clin Psychopharmacol; 2007 Jan; 22(1):51-5. PubMed ID: 17159460
[TBL] [Abstract][Full Text] [Related]
20. Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies.
Spellmann I; Schennach R; Seemüller F; Meyer S; Musil R; Jäger M; Schmauß M; Laux G; Pfeiffer H; Naber D; Schmidt LG; Gaebel W; Klosterkötter J; Heuser I; Bauer M; Adli M; Zeiler J; Bender W; Kronmüller KT; Ising M; Brieger P; Maier W; Lemke MR; Rüther E; Klingberg S; Gastpar M; Riedel M; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 2017 Jun; 267(4):303-313. PubMed ID: 27785605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
